Clinical Trial: A Phase 2 Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria

U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07796256) titled 'A Phase 2 Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria' on Aug. 27.

Brief Summary: This is a multicenter, randomized, open-Label Phase II study to evaluate the efficacy and safety of multiple doses of SGB-9768 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: PNH - Paroxysmal Nocturnal Hemoglobinuria

Intervention: DRUG: SGB-9768

SGB-9768 will be administered by subcutaneous injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Suzhou Sanegene Bio Inc.

Published by HT Digital Content Services with permission from H...